August 22, 2019 Astra could use a voucher to cement roxadustat’s head start Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
May 31, 2019 Upcoming events – Anaptysbio and Retrophin await big readouts Anaptysbio’s etokimab needs to beat Dupixent, while Retrophin takes aims at an underserved rare disease.
May 30, 2019 Go or no go? Merck, Regeneron and Alexion await US expansion Approvals for new uses of old drugs should far outweigh nods for novel projects in June.